Effect of blood glucose level on the prognosis of breast cancer patients with type 2 diabetes mellitus / 肿瘤研究与临床

ABSTRACT

Objective To investigate the impact of blood glucose level on the prognosis of breast cancer patients with type 2 diabetes mellitus. Methods Clinical data of 416 breast cancer patients with type 2 diabetes mellitus in Tianjin Medical University Cancer Institute and Hospital from January 2005 to December 2009 were analyzed retrospectively. Patients were divided into 2 groups according to the postprandial 2 hours of blood glucose level (＜11.1 mmol/L and ≥11.1 mmol/L). Clinicopathological characteristics and survival of the two groups were compared. Results There were 310 cases of postprandial 2 hours of blood glucose level (＜11.1 mmol/L), and 106 cases of postprandial 2 hours of blood glucose level (≥11.1 mmol/L) in 416 patients. There was no statistical difference in the clinicopathological features between the two groups (both P＞ 0.05). Univariate analysis showed that the 5-year disease-free survival rate was 81.6 % (253/310) and 67.0 % (71/106) for patients with postprandial 2 hours of blood glucose level＜11.1 mmol/L and postprandial 2 hours of blood glucose level ≥11.1 mmol/L, respectively (χ2= 8.575, P=0.003). The 5-year overall survival rate was 87.7 % (272/310) and 75.5 % (80/106) for patients with postprandial 2 hours of blood glucose level ＜11.1 mmol/L and postprandial 2 hours of blood glucose level≥11.1 mmol/L, respectively (χ2=8.722, P =0.003). Multivariate analysis showed that 2 hours of blood glucose level≥11.1 mmol/L was an independent risk factor of 5-year disease-free survival rate ( HR=1.701, 95 % CI 1.110-2.604, P= 0.015) and 5-year overall survival rate ( HR= 1.972, 95 % CI 1.186-3.279, P= 0.009) for diabetic breast cancer patients. Conclusion The poor control of blood glucose level for the breast cancer patients complicated with type 2 diabetes is related with the increased risk of 5-year recurrence and death, which requires to strictly control the blood glucose level for improving the prognosis of type 2 diabetic breast cancer patients.